Specialty Considerations in the Management of Hepatitis C

Activity Preview

Chronic hepatitis C virus (HCV) infections pose a substantial public health burden globally with an estimated 71 million people with chronic HCV. The prevalence of HCV varies by country and region. In the United States (U.S.), more than 3 million persons have HCV. Although not all individuals exposed to HCV go on to develop chronic infection, most do and are at risk for developing complications such as cirrhosis, end-stage liver disease, and hepatocellular carcinoma (HCC), and ultimately die as a result of their infection. Disease progression is variable and often asymptomatic until complications of chronic HCV arise. Interest in chronic HCV management increased with new drug approvals however concerns for cost of therapy continues to limit patient access to treatment. Criteria used to determine HCV treatment candidacy including staging of liver disease and need for liver biopsy, alcohol and substance abuse screening, ability to use short-course therapy, challenges of genotype 3 infection, and the potential pitfalls of strict restrictions during HCV therapy are examined using clinical case scenarios.

Learning Objectives: 

At the completion of this activity, the pharmacist will be able to:

1. Describe the clinical and economic burden associated with hepatitis C virus (HCV) infection

2. Discuss the importance of early assessment of high-risk patients and the rationale for early treatment of patients with HCV infection

3. Distinguish new and emerging agents for the treatment of patients infected with HCV

4. Use national algorithms and guidelines to guide treatment strategies for patients with HCV infection

5. Examine managed care considerations in the management of HCV, including strategies for determining cost-effectiveness of treatment and the impact of changing treatment outcomes on managed care organizations

Activity type: Knowledge-based

Target Audience: Pharmacists

Learning level: 1

Accreditation Information

The American Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  This activity is approved for 2.0 contact hours of CPE credit (0.20 CEUs). The ACPE Universal Activity Number for this activity is 0202-0000-17-252-H01-P.

To obtain credit for "Specialty Considerations in the Management of Hepatitis C," complete the assessment with a grade of 70% or better, both evaluations, and then claim credit. Participants need to have a valid pharmacist.com username and password to claim credit. After credit has been claimed, please visit CPE monitor for your transcript.

APhA continuing pharmacy education policy allows two opportunities to successfully complete the continuing pharmacy education assessment. Please note that the questions may not appear in the same order as printed and you will not be permitted to submit the assessment a third time. The current policy of the APhA Education Department is to not release the correct answers to any of our CPE tests. This policy is intended to maintain the integrity of the CPE activity and the assessment.

Initial release date: November 1, 2017
Expiration date: November 1, 2020 - NO CREDIT GRANTED AFTER THIS DATE

Development

"Specialty Considerations in the Management of Hepatitis C” is a home-study continuing education activity for pharmacists developed by the American Pharmacists Association.

Authors

Paulina Deming, PharmD, PhC

Associate Professor, College of Pharmacy

Assistant Director, Hepatitis C Programs

ECHO InstituteTM

University of New Mexico Health Sciences Center

1 University of New Mexico MSC07 4245

Albuquerque, NM 87131

pdeming@salud.unm.edu

Linda Spooner, PharmD, RPh, BCPS (AQ-ID), FASHP, FCCP

Professor of Pharmacy Practice

Pharmacy Practice

MCPHS University

19 Foster Street

Worcester, MA 01608

linda.spooner@mcphs.edu

Advisory Board

David Quan, PharmD, BCPS

Pharmacist Specialist – Solid Organ Transplant

Pharmaceutical Services

UCSF Medical Center

San Francisco, CA

Disclosures

Paulina Deming, PharmD, PhC, declares that she is an advisor for Gilead.

Linda Spooner, PharmD, RPh, BCPS (AQ-ID), FASHP, FCCP; David Quan, PharmD, BCPS; and APhA’s editorial staff declare no conflicts of interest or financial interests in any product or service mentioned in this activity, including grants, employment, gifts, stock holdings, and honoraria. For complete staff disclosures, please see the Education and Accreditation Information section at www.pharmacist.com/apha-disclosures.

Fee

There is no fee associated with this activity for members of the American Pharmacists Association. There is a $25 fee for nonmembers.

System Requirements

Computer and Internet access is required to complete this activity.  Please visit our website to view the Technology System Requirements to have a positive learning experience.

Credit Information

Activity Number Credit Amount Accreditation Period
ACPE# 0202-0000-17-252-H01-P 0.2 CEUs November 01, 2017 - November 01, 2020